Maravai LifeSciences Holdings logo
Maravai LifeSciences Holdings MRVI
$ 6.99 -3.59%
report update icon

Quarterly report 2026-Q3
added 11-05-2026

Maravai LifeSciences Holdings Revenue | MRVI

Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.

Traditionally defined as follows:
Revenue = Price * Quantity of products

Revenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]

This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.

Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.

Annual Revenue Maravai LifeSciences Holdings

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
186 M 259 M 289 M 883 M 799 M 284 M 143 M 124 M - - - - - - -

All numbers in USD currency

Indicator range from annual reports

Maximum Minimum Average
883 M 124 M 371 M

Quarterly Revenue Maravai LifeSciences Holdings

2026-Q3 2026-Q2 2026-Q1 2025-Q4 2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1
45.9 M 51.4 M 65.8 M 49.9 M 41.6 M 47.4 M 46.8 M 56.6 M 69 M 69.4 M 64.2 M 74.1 M 66.9 M 68.9 M 79 M 205 M 191 M 243 M 244 M 228 M 205 M 218 M 148 M - 87.9 M 46.9 M 51 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

Indicator range from quarterly reporting

Maximum Minimum Average
244 M 41.6 M 106 M

References

  1. Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).

Revenue of other stocks in the Biotechnology industry

Issuer Revenue Price % 24h Market Cap Country
SpringWorks Therapeutics SpringWorks Therapeutics
SWTX
192 M - - $ 3.48 B usaUSA
Axon Enterprise Axon Enterprise
AXON
2.78 B $ 291.02 -5.2 % $ 22.7 B usaUSA
Infinity Pharmaceuticals Infinity Pharmaceuticals
INFI
2.59 M - -46.98 % $ 3.57 M usaUSA
Ayala Pharmaceuticals Ayala Pharmaceuticals
AYLA
692 K - - $ 7.46 M israelIsrael
Morphic Holding Morphic Holding
MORF
521 K - - $ 2.42 B usaUSA
Genocea Biosciences Genocea Biosciences
GNCA
1.64 M - -15.0 % $ 3.04 M usaUSA
Biogen Biogen
BIIB
9.89 B $ 249.55 0.98 % $ 36.6 B usaUSA
Bristol-Myers Squibb Company Bristol-Myers Squibb Company
BMY
48.2 B $ 58.74 0.69 % $ 119 B usaUSA
Eiger BioPharmaceuticals Eiger BioPharmaceuticals
EIGR
15.8 M - -9.21 % $ 2.55 M usaUSA
Merrimack Pharmaceuticals Merrimack Pharmaceuticals
MACK
144 M - - $ 216 M usaUSA
Mirati Therapeutics Mirati Therapeutics
MRTX
12.4 M - - $ 3.3 B usaUSA
Bellicum Pharmaceuticals Bellicum Pharmaceuticals
BLCM
1.5 M - -9.72 % $ 5.89 M usaUSA
Orchard Therapeutics plc Orchard Therapeutics plc
ORTX
22.7 M - 1.02 % $ 90.8 M britainBritain
La Jolla Pharmaceutical Company La Jolla Pharmaceutical Company
LJPC
75.7 M - - $ 154 M usaUSA
Oyster Point Pharma Oyster Point Pharma
OYST
24.5 M - - $ 300 M usaUSA
Intercept Pharmaceuticals Intercept Pharmaceuticals
ICPT
77.2 M - - $ 643 M usaUSA
Chinook Therapeutics Chinook Therapeutics
KDNY
6.13 M - - $ 2.6 B usaUSA
Syros Pharmaceuticals Syros Pharmaceuticals
SYRS
9.94 M - -8.44 % $ 3.4 M usaUSA
GT Biopharma GT Biopharma
GTBP
27 K $ 2.93 -7.86 % $ 16.2 M usaUSA
Zymeworks Zymeworks
ZYME
26.7 M $ 26.41 -1.68 % $ 1.36 B canadaCanada
Citius Pharmaceuticals Citius Pharmaceuticals
CTXR
90 K $ 0.51 1.61 % $ 5.64 M usaUSA
Cytokinetics, Incorporated Cytokinetics, Incorporated
CYTK
88 M $ 50.7 -1.48 % $ 6.09 M usaUSA
DBV Technologies S.A. DBV Technologies S.A.
DBVT
5.64 M $ 9.03 -4.14 % $ 1.26 B franceFrance
Precision BioSciences Precision BioSciences
DTIL
34.3 M $ 7.37 6.66 % $ 94.5 M usaUSA
Exelixis Exelixis
EXEL
2.32 B $ 64.59 -1.88 % $ 17.5 B usaUSA
Fennec Pharmaceuticals Fennec Pharmaceuticals
FENC
44.6 M $ 13.09 -2.68 % $ 374 M usaUSA
Cardiff Oncology Cardiff Oncology
CRDF
593 K $ 0.85 -4.67 % $ 56.8 M usaUSA
BioNTech SE BioNTech SE
BNTX
482 M $ 80.87 -0.63 % $ 19.5 B germanyGermany
Alkermes plc Alkermes plc
ALKS
1.48 B $ 44.89 -2.79 % $ 7.39 B irlandaIrlanda
ANI Pharmaceuticals ANI Pharmaceuticals
ANIP
883 M $ 68.6 -0.77 % $ 1.38 B usaUSA
AIM ImmunoTech AIM ImmunoTech
AIM
88 K $ 0.11 -7.75 % $ 178 K usaUSA
AC Immune SA AC Immune SA
ACIU
3.57 M $ 1.98 -7.28 % $ 199 M schweizSchweiz
Atara Biotherapeutics Atara Biotherapeutics
ATRA
121 M $ 6.51 2.6 % $ 81.7 M usaUSA
Allogene Therapeutics Allogene Therapeutics
ALLO
22 K $ 0.63 -5.62 % $ 139 M usaUSA
Altimmune Altimmune
ALT
41 K $ 1.33 -6.03 % $ 117 M usaUSA
AnaptysBio AnaptysBio
ANAB
53 M $ 46.65 -1.58 % $ 1.35 B usaUSA
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
12.1 K - -1.52 % $ 24.7 M usaUSA
Ascendis Pharma A/S Ascendis Pharma A/S
ASND
720 M $ 252.39 -1.39 % $ 15.3 B danmarkDanmark
Arcturus Therapeutics Holdings Arcturus Therapeutics Holdings
ARCT
82 M $ 7.42 -2.37 % $ 203 M israelIsrael
Aurinia Pharmaceuticals Aurinia Pharmaceuticals
AUPH
77.1 M $ 14.7 -1.28 % $ 1.98 B canadaCanada
Autolus Therapeutics plc Autolus Therapeutics plc
AUTL
75.4 M $ 0.91 -6.96 % $ 242 M britainBritain
Atea Pharmaceuticals Atea Pharmaceuticals
AVIR
351 M $ 3.97 0.89 % $ 324 M usaUSA